Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Abbv crawled date : 2022 - 03 - 10 save search
AbbVie Prepares to Seek Supplemental Approval for Migraine Treatment
Published: 2022-03-10 (Crawled : 19:00) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
treatment approval migraine
AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine
Published: 2022-03-10 (Crawled : 13:30) - prnewswire.com
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
treatment pos migraine positive phase 3
Anterior Uveitis Treatment Market 2022-2026 | Increasing Healthcare Spending Worldwide to Boost Growth | Technavio
Published: 2022-03-10 (Crawled : 12:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.14%
H: 2.48%
C: 2.48%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -1.76%
H: 2.09%
C: 0.6%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 2.3%
H: 0.0%
C: 0.0%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.09%
H: 1.7%
C: 1.12%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
treatment health thc growth
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.